Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Pharmacology stubs
Deucravacitinib
Другие языки:

Deucravacitinib

Подписчиков: 0, рейтинг: 0

Deucravacitinib
Deucravacitinib.svg
Clinical data
Pronunciation /duːˌkrævəˈsɪtɪnɪb/
doo-KRA-və-SI-ti-nib
Trade names Sotyktu
Other names BMS-986165
AHFS/Drugs.com Monograph
License data
Pregnancy
category
  • AU: B1
Routes of
administration		 By mouth
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability 99%
Protein binding 82–90%
Metabolism Liver (primarily CYP1A2)
Metabolites BMT-153261 (active)
Elimination half-life 10 hours
Excretion Feces, urine
Identifiers
  • 6-(Cyclopropanecarbonylamido)-4-[2-methoxy-3-(1-methyl-1,2,4-triazol-3-yl)anilino]-N- (trideuteriomethyl)pyridazine-3-carboxamide
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
ECHA InfoCard 100.329.069
Chemical and physical data
Formula C20H19D3N8O3
Molar mass 425.466 g·mol−1
3D model (JSmol)
  • [2H]C([2H])([2H])NC(=O)C1=NN=C(C=C1NC2=CC=CC(=C2OC)C3=NN(C=N3)C)NC(=O)C4CC4
  • InChI=1S/C20H22N8O3/c1-21-20(30)16-14(9-15(25-26-16)24-19(29)11-7-8-11)23-13-6-4-5-12(17(13)31-3)18-22-10-28(2)27-18/h4-6,9-11H,7-8H2,1-3H3,(H,21,30)(H2,23,24,25,29)/i1D3
  • Key:BZZKEPGENYLQSC-FIBGUPNXSA-N

Deucravacitinib, sold under the brand name Sotyktu, is medication used for the treatment of moderate-to-severe plaque psoriasis. It is a tyrosine kinase 2 (TYK2) inhibitor and it is taken by mouth. It was developed by Bristol Myers Squibb.

Deucravacitinib was approved for medical use in the United States in September 2022, and in Australia in December 2022. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.

Medical uses

Deucravacitinib is being developed by Bristol Myers Squibb for the treatment of multiple immune-mediated diseases, including psoriasis, psoriatic arthritis, lupus and inflammatory bowel disease. It received its first approval (in the USA on 9 September 2022) for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Mechanism of action

It acts as a highly selective allosteric inhibitor of non-receptor tyrosine-protein kinase 2 (TYK2).

Molecule design

The chemical structure of deucravacitinib contains a methyl amide in which all three hydrogen atoms are replaced by deuterium.

Society and culture

Legal status

On 26 January 2023, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Sotyktu, intended for the treatment of moderate to severe psoriasis. The applicant for this medicinal product is Bristol-Myers Squibb Pharma EEIG. Deucravacitinib was approved for medical use in the European Union in March 2023.

External links



Новое сообщение